Are CME providers being used by the pharmaceutical industry to legitimize a treatment for conditions that aren't really diseases? Did Glaxo SmithKline “invent” irritable bowel syndrome in part by underwriting CME on the subject? These uncomfortable questions have been raised in an article in the April 13 issue of BMJ (formerly known as the British Medical Journal). In “Selling Sickness: The Pharmaceutical Industry and Disease Mongering,” authors Ray Moynihan, a journalist with the ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only unlock thePrinter-friendly, you'll also gain access to exclusive premium content.

Already registered? here.